

First comprehensive cancer multi-omics data portal launches in India

22 September 2024 | News

For empowering researchers with crucial data to advance customised cancer research



The Indian Cancer Genome Atlas (ICGA), a national initiative focused on mapping the genomic, transcriptomic, and proteomic landscapes of cancers across India, has launched India's first comprehensive cancer multi-omics data portal. This pioneering platform provides open access to clinically correlated data from Indian cancer patients, aimed at transforming cancer research and treatment for Indian populations.

The ICGA cancer multi-omics portal is the first in India to offer data that includes DNA, RNA, and protein profiles of breast cancer patients, integrated with clinical outcomes. Currently, the platform consists of data from 50 breast cancer patients, with plans to expand to over 500 patients in the coming year. This data is freely accessible to the global research community under India's PRIDE guidelines, which promote ethical sharing and collaboration in cancer research.

Key Highlights of this portal include:

- India's First Cancer Multi-Omics Data Portal: A comprehensive resource that offers detailed multi-omics data for breast cancer patients, including genomic and proteomic information.
- Based on cBioPortal Platform: Derived from the internationally recognised cBioPortal, this platform ensures seamless integration with global cancer research efforts.
- Initial Dataset from 50 Indian Patients: Provides clinically annotated DNA, RNA, and protein profiles, along with treatment histories and patient outcomes, with an aim to scale up to 500 in a year.
- Free Access Under PRIDE Guidelines: Adhering to responsible and ethical data-sharing practices, the portal is freely accessible to the scientific community.
- A Step Toward Precision Oncology for Indian Patients: This initiative is designed to enable the development of personalized cancer treatments tailored to Indian patients.
- Call for Collaboration: ICGA invites researchers worldwide to contribute and expand the platform, fostering global collaboration in cancer research.